image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 15.74
-2.72 %
$ 4.05 B
Market Cap
3.12
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one OGN stock under the worst case scenario is HIDDEN Compared to the current market price of 15.7 USD, Organon & Co. is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one OGN stock under the base case scenario is HIDDEN Compared to the current market price of 15.7 USD, Organon & Co. is HIDDEN

This DCF valuation model was last updated on Jan, 19, 2025.

The intrinsic value of one OGN stock under the best case scenario is HIDDEN Compared to the current market price of 15.7 USD, Organon & Co. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
6.26 B REVENUE
1.44%
1.33 B OPERATING INCOME
-10.22%
1.02 B NET INCOME
11.56%
799 M OPERATING CASH FLOW
-6.88%
-260 M INVESTING CASH FLOW
38.10%
-569 M FINANCING CASH FLOW
-31.41%
1.58 B REVENUE
-1.56%
390 M OPERATING INCOME
1.04%
359 M NET INCOME
84.10%
141 M OPERATING CASH FLOW
-57.53%
142 M INVESTING CASH FLOW
408.22%
-78 M FINANCING CASH FLOW
41.79%
Balance Sheet Organon & Co.
image
Current Assets 4.51 B
Cash & Short-Term Investments 693 M
Receivables 1.74 B
Other Current Assets 2.07 B
Non-Current Assets 7.55 B
Long-Term Investments 0
PP&E 1.18 B
Other Non-Current Assets 6.37 B
Current Liabilities 2.92 B
Accounts Payable 1.31 B
Short-Term Debt 9 M
Other Current Liabilities 1.6 B
Non-Current Liabilities 9.21 B
Long-Term Debt 8.88 B
Other Non-Current Liabilities 334 M
EFFICIENCY
Earnings Waterfall Organon & Co.
image
Revenue 6.26 B
Cost Of Revenue 2.52 B
Gross Profit 3.75 B
Operating Expenses 2.42 B
Operating Income 1.33 B
Other Expenses 304 M
Net Income 1.02 B
RATIOS
59.84% GROSS MARGIN
59.84%
21.19% OPERATING MARGIN
21.19%
16.33% NET MARGIN
16.33%
-1461.43% ROE
-1461.43%
8.48% ROA
8.48%
23.21% ROIC
23.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Organon & Co.
image
Net Income 1.02 B
Depreciation & Amortization 236 M
Capital Expenditures -261 M
Stock-Based Compensation 101 M
Change in Working Capital -155 M
Others 203 M
Free Cash Flow 538 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Organon & Co.
image
Wall Street analysts predict an average 1-year price target for OGN of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OGN Lowest Price Target Wall Street Target
24 USD 52.48%
OGN Average Price Target Wall Street Target
24 USD 52.48%
OGN Highest Price Target Wall Street Target
24 USD 52.48%
4. DIVIDEND ANALYSIS
1.50% DIVIDEND YIELD
0.28 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Organon & Co.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
49.9 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
10 months ago
Feb 22, 2024
Bought 49.9 K USD
Weaver Kirke
Gen. Counsel & Corp. Secy.
+ 2720
18.3599 USD
3 years ago
Aug 19, 2021
Bought 101 K USD
Francisco Ma. Fatima
Director
+ 3000
33.79 USD
7. News
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com - 2 weeks ago
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks. Investing in dividend stocks can be an excellent way to boost your income each year. But the challenge can be generating a good return while keeping your risk low. fool.com - 2 weeks ago
Organon (OGN) Ascends While Market Falls: Some Facts to Note Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day. zacks.com - 3 weeks ago
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. zacks.com - 4 weeks ago
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th. businesswire.com - 1 month ago
Organon price target raised to $20 from $19 at Goldman Sachs Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA's AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note. https://thefly.com - 1 month ago
Final Trades: Amazon, American Express and Organon The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half. youtube.com - 1 month ago
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 1 month ago
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com - 1 month ago
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 2 months ago
Organon: 7% Yield, 4x P/E, Big Upside Potential Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas. seekingalpha.com - 2 months ago
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt. seekingalpha.com - 2 months ago
8. Profile Summary

Organon & Co. OGN

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 4.05 B
Dividend Yield 1.50%
Description Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Contact 30 Hudson Street, Jersey City, NJ, 07302 https://www.organon.com
IPO Date May 14, 2021
Employees 10000
Officers Mr. Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing & Supply Mr. Daniel Karp Executive Vice President of Corporate Development Ms. Susan O'Neal Chief Ethics & Compliance Officer Ms. Rachel A. Stahler Executive Vice President & Chief Information Officer Ms. Jennifer Halchak Head of Investor Relations Mr. Matthew M. Walsh C.F.A. Executive Vice President & Chief Financial Officer Ms. Susanne Gabriele Fiedler Executive Vice President & Chief Commercial Officer Ms. Rebecca Lowell Edwards Chief Communications Officer Mr. Kevin Ali Chief Executive Officer & Director Mr. Kirke Weaver Executive Vice President, General Counsel & Corporate Secretary